Cancer Screening, Current

Three cancer screens demonstrably save women's lives; every one of them also carries a genuine, unresolved argument about exactly when to start and how often to repeat. This page walks the three windows — breast, cervical, colorectal — plus the narrow lung window, and separates the real debates from noise, including what the newest blood tests cannot claim yet.

The Ledger in One Chart

Before the debates, the scoreboard. Each screen below answers the same question — how much did it cut its cancer's death rate in the key trials — and the answers vary more than most checklists admit. The colonoscopy bar deserves the closest look: it is not a verdict against the test; it is a lesson about what happens when a screening program meets real people.

Mammography: The 40 Versus 45 Versus 50 Argument

The same randomized trials, read three ways. The USPSTF's 2024 statement recommends biennial mammography from 40 to 74 — a move down from its previous start age of 50. The American Cancer Society favors starting at 45 with annual screening through 54, then biennial. ACOG holds the line at 40, every one to two years. All three cite the same trial evidence; they weight the same two columns differently — lives saved versus false positives, anxiety, biopsies, and overdiagnosis.

• 📉 The mortality benefit is real but modest. Pooled estimates put it at roughly 14% for women in their 50s and 60s, and smaller in the 40s, where fewer cancers occur.
• 🎭 The false-positive column is the price. Ten years of annual mammograms carry close to a coin-flip chance of at least one recall — extra imaging, sleepless weeks, and a biopsy that turns out benign.
• 🫥 Overdiagnosis is the quiet third column. Estimates typically land around 10–20% of screen-detected cancers — tumors that would never have caused harm — though honest models disagree widely on the exact figure.
• 🌫️ Breast density complicates everything. Roughly half of women have dense breasts, which both hide cancers on a standard mammogram and raise risk itself; the USPSTF found the evidence insufficient to recommend routine supplemental imaging for dense breasts.
• 🤝 The defensible position is shared decision-making. Family history, density, prior biopsies, and personal tolerance for the false-positive column are the variables — which is precisely why the guideline split exists.

Cervical: The Clearest Win, With a New Twist

Cervical screening is the undisputed success of the list — the American Cancer Society's 2020 guideline recommends primary HPV testing every five years from 25 through 65, with Pap testing every three years as an acceptable alternative. Wherever organized screening took hold, cervical cancer incidence collapsed — in the US it has fallen by more than half since the mid-1970s. And the story is still improving: HPV vaccination, given before exposure, is shrinking the disease at the source. Among Swedish women vaccinated before age 17, invasive cervical cancer was roughly 88% lower than in unvaccinated women (Lei et al., NEJM, 2020). For a vaccinated woman in her 30s or 40s the schedule is unchanged for now, but the risk she is screening against has already dropped, and future guidelines will likely reflect that. The stop rule — screening ends at 65 with an adequate prior record — is covered on the decade map.

Colorectal: The 45 Start and the Colonoscopy Question

The start age moved from 50 to 45 in 2021 because colorectal cancer is rising in younger adults, and screening from 45 through 75 is now an A-grade USPSTF recommendation. The modality menu is wider than most women realize: colonoscopy every ten years, a FIT stool test every year, a FIT-DNA test every three years, CT colonography every five years, or flexible sigmoidoscopy every five years. The honest evidence twist came from NordICC, the large randomized trial of colonoscopy itself: people invited to screening had 18% lower colorectal cancer incidence, but no statistically significant reduction in colorectal cancer mortality — because only about 42% of those invited actually showed up for the scope. In the adherence-adjusted analysis, the effect roughly doubled. The lesson is not that colonoscopy fails; it is that a screening test only works at the rate people complete it, which is why guideline bodies keep repeating that any completed modality beats none. If a scope feels like too much, annual FIT is a legitimate choice — its one weakness is skipped years, and a positive result needs a follow-up colonoscopy.

Lung: The Narrowest Window

Low-dose CT screening for lung cancer is one of the strongest results in screening history — the National Lung Screening Trial found a 20% reduction in lung cancer mortality — but the window is deliberately narrow. It opens only for women aged 50 to 80 with a 20-pack-year smoking history who smoke now or quit within the past 15 years, and it closes when 15 years of cessation have passed. For everyone else, the false-positive rate of lung CT outweighs the benefit, which is why no guideline body recommends it for never-smokers regardless of age. If you are anywhere near that window, it is the conversation most worth having this decade; if you are not, the test is not for you.

The Multi-Cancer Blood Test Question

The newest entry in the screening conversation is the multi-cancer early detection blood test — a single draw screened for fragments of tumor DNA across dozens of cancers. The appeal is obvious: instead of five separate schedules, one test. The evidence, so far, is not there yet. No completed trial has shown these tests reduce cancer mortality, no major guideline body recommends them outside research, and the early data carry open questions about false positives and about whether finding certain cancers earlier actually changes outcomes. Large trials are running, and the position may change — but as of mid-2026 the honest status is promising, unproven, and not a substitute for the windows on this page. The three questions to ask before any screen — absolute risk, false-positive consequences, and whether a positive result would change what you do — apply here with extra force, and they are exactly the questions the advocacy guide turns into a script.

Questions, Answered Briefly

• 🎀 Should I get annual or biennial mammograms? The USPSTF says biennial 40–74; annual adds roughly twice the false positives for a smaller added benefit. If your risk profile — density, family history — pushes toward annual, that is a clinician conversation, not a default.
• 🌸 I was vaccinated against HPV — do I still screen? Yes, on the current schedule. Your underlying risk is substantially lower, which is excellent news, but the guidelines have not yet adjusted the schedule for vaccinated cohorts.
• 🩺 Is FIT as good as colonoscopy? Done yearly, FIT performs comparably on colorectal cancer mortality in the evidence, and colonoscopy found more adenomas. The deciding variable is which one you will actually complete on schedule.
• 🧪 Should I pay out of pocket for a multi-cancer blood test? As of mid-2026, no major body recommends them outside trials and no mortality benefit has been shown. If the trials succeed, this answer changes — and the Quarterly Audit is the place to track that news.
• 🫁 I smoked for years but quit at 45 — do I qualify for lung CT? Only if you quit within the past 15 years and reached 20 pack-years; past that, the window has closed, which is the trial evidence working in your favor.

Related Topics